TWiV 1289: Building a better hepatitis B trap

This episode of TWIV explores the pathogenesis of dengue virus and potential therapeutic strategies for hepatitis B. The panel discusses a study revealing how the dengue virus NS1 protein compromises the mosquito midgut, facilitating viral dissemination and potentially offering a novel target for dengue control. They examine another paper focused on a capsid assembly modulator, GLP-26, in treating chronic hepatitis B, noting its ability to suppress viral replication and promote a functional cure by revitalizing exhausted T cells and stimulating antibody production in humanized mice. The discussion highlights the potential of GLP-26 to break immune tolerance and achieve lasting viral control after treatment interruption, a significant improvement over existing therapies. The team also touches on practical matters such as the importance of Hep B vaccination and difficulties in getting insurance coverage for shingles vaccines for younger patients.